Serenity Pharmaceuticals, Inc.

Quick facts

Phase 3 pipeline

• SER120 · Psychiatry
  SER120 is a small molecule that targets the serotonin receptor.
• SER120 1500 ng
  SER120 is an investigational therapeutic agent in Phase 3 development by Serenity Pharmaceuticals with an undisclosed mechanism of action.
• SER120 750 ng · Psychiatry
  SER120 is a small molecule that targets the serotonin receptor.
• SER120 Nasal Spray 500 ng/day
  SER120 is an investigational nasal spray formulation with an unknown mechanism of action.
• SER120 nasal spray 750 ng/day · Psychiatry
  SER120 is a serotonin receptor agonist.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Serenity Pharmaceuticals, Inc. portfolio CI brief
• Serenity Pharmaceuticals, Inc. pipeline updates RSS